Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Jun;35(6):e41.
doi: 10.2337/dc12-0115.

Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy

Claudia Cavelti-Weder, Bettina Muggli, Cornelia Keller, Andrea Babians-Brunner, Anna Biason-Lauber, Marc Y Donath, Peter Schmid-Grendelmeier
Case Reports

Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy

Claudia Cavelti-Weder et al. Diabetes Care. 2012 Jun.
No abstract available

PubMed Disclaimer

References

    1. Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy 2008;63:148–155 - PubMed
    1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–316 - PubMed
    1. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125:383–389 - PubMed
    1. Yong PFK, Malik R, Arif S, et al. Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 2009;360:1045–1047 - PubMed
    1. Matheu V, Franco A, Perez E, Hernández M, Barrios Y. Omalizumab for drug allergy. J Allergy Clin Immunol 2007;120:1471–1472 - PubMed

MeSH terms